Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 579-588 , July 2008

Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

  • Reinhard Meier

      Affiliations

    • Department of Radiology, University of California San Francisco, USA
    • Corresponding Author InformationCorresponding author. Tel.: +49 178 7879781.
    • ,
  • Morand Piert

      Affiliations

    • Department of Radiology, Division of Nuclear Medicine, University of Michigan, USA
    • ,
  • Guido Piontek

      Affiliations

    • Institute of Pathology, Klinikum rechts der Isar, Technische Universität München, Germany
    • ,
  • Martina Rudelius

      Affiliations

    • Institute of Pathology, Klinikum rechts der Isar, Technische Universität München, Germany
    • ,
  • Robert A. Oostendorp

      Affiliations

    • 3rd Department of Internal Medicine, Klinikum rechts der Isar, Technische Universität München, Germany
    • ,
  • Reingard Senekowitsch-Schmidtke

      Affiliations

    • Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Germany
    • ,
  • Tobias D. Henning

      Affiliations

    • Department of Radiology, University of California San Francisco, USA
    • ,
  • Winfried S. Wels

      Affiliations

    • Chemotherapeutisches Forschungsinstitut, Georg-Speyer-Haus, Frankfurt am Main, Germany
    • ,
  • Christoph Uherek

      Affiliations

    • Chemotherapeutisches Forschungsinstitut, Georg-Speyer-Haus, Frankfurt am Main, Germany
    • ,
  • Ernst J. Rummeny

      Affiliations

    • Department of Radiology, Klinikum rechts der Isar, Technische Universität München, Germany
    • ,
  • Heike E. Daldrup-Link

      Affiliations

    • Department of Radiology, University of California San Francisco, USA

Received 6 October 2007 ,Revised 8 February 2008 ,Accepted 28 February 2008.

References 

  1. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat. 2007;104(3):267–275Epub 2006 Oct 26
  2. Stein MN, Shin J, Gudzowaty O, Bernstein AM, Liu JM. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res. 2006;26(3A):1759–1763
  3. Tam YK, Miyagawa B, Ho VC, Klingemann HG. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother. 1999;8(3):281–290
  4. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291–330
  5. Whiteside TL. Immune cells in the tumor microenvironment—mechanisms responsible for functional and signaling defects. Gene Therapy of Cancer. 1998;451:167–171
  6. Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM. A Phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer. 2001;31(1):67–72
  7. Maraninchi D, Vey N, Viens P, Stoppa AM, Archimbaud E, Attal M, et al. A Phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma. 1998;31(3–4):343–349
  8. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10(4):535–544
  9. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res. 1998;4(11):2859–2868
  10. Klingemann HG, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant. 1996;2(2):68–75
  11. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100(4):1265–1273
  12. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000;77:25–79
  13. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19(13):3159–3167
  14. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005;15(1):4–13
  15. Fawwaz RA, Oluwole S, Wang TS, Kuromoto N, Iga C, Hardy MA, et al. Biodistribution of radiolabeled lymphocytes. Radiology. 1985;155(2):483–486
  16. Melder RJ, Brownell AL, Shoup TM, Brownell GL, Jain RK. Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. Cancer Res. 1993;53(24):5867–5871
  17. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME, et al. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A. 2002;99(5):3030–3035
  18. Moore A, Grimm J, Han B, Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes. 2004;53(6):1459–1466
  19. Oostendorp RA, Ghaffari S, Eaves CJ. Kinetics of in vivo homing and recruitment into cycle of hematopoietic cells are organ-specific but CD44-independent. Bone Marrow Transplant. 2000;26(5):559–566
  20. Daldrup-Link HE, Rudelius M, Metz S, Piontek G, Pichler B, Settles M, et al. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging. 2004;31(9):1312–1321
  21. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000;18(4):410–414
  22. Daldrup-Link HE, Rudelius M, Piontek G, Metz S, Brauer R, Debus G, et al. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology. 2005;234(1):197–205
  23. Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny EJ, Daldrup-Link HE. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol. 2004;14(10):1851–1858
  24. Schoepf U, Marecos EM, Melder RJ, Jain RK, Weissleder R. Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques. 1998;24(4):642–651
  25. Smirnov P, Gazeau F, Lewin M, Bacri JC, Siauve N, Vayssettes C, et al. In vivo cellular imaging of magnetically labeled hybridomas in the spleen with a 1.5-T clinical MRI system. Magn Reson Med. 2004;52(1):73–79
  26. Weissleder R, Cheng HC, Bogdanova A, Bogdanov A. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging. 1997;7(1):258–263
  27. Yeh TC, Zhang W, Ildstad ST, Ho C. In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles. Magn Reson Med. 1995;33(2):200–208
  28. Melder RJ, Elmaleh D, Brownell AL, Brownell GL, Jain RK. A method for labeling cells for positron emission tomography (PET) studies. J Immunol Methods. 1994;175(1):79–87
  29. Forstrom LA, Mullan BP, Hung JC, Lowe VJ, Thorson LM. 18F-FDG labelling of human leukocytes. Nucl Med Commun. 2000;21(7):691–694
  30. Kang WJ, Kang HJ, Kim HS, Chung JK, Lee MC, Lee DS. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med. 2006;47(8):1295–1301
  31. Pellegrino D, Bonab AA, Dragotakes SC, Pitman JT, Mariani G, Carter EA. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med. 2005;46(9):1522–1530
  32. Rini JN, Bhargava KK, Tronco GG, Singer C, Caprioli R, Marwin SE, et al. PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. Radiology. 2006;238(3):978–987
  33. Ritchie D, Mileshkin L, Wall D, Bartholeyns J, Thompson M, Coverdale J, et al. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother. 2007;56(2):155–163
  34. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27(2):235–238
  35. Paik JY, Lee KH, Byun SS, Choe YS, Kim BT. Use of insulin to improve [18F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking. Nucl Med Commun. 2002;23(6):551–557
  36. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–726
  37. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684
  38. Uherek C, Groner B, Wels W. Chimeric antigen receptors for the retargeting of cytotoxic effector cells. J Hematother Stem Cell Res. 2001;10(4):523–534
  39. Bai J, Ding W, Yu M, Du J, Liu Z, Jia B, et al. Radionuclide imaging of mesenchymal stem cells transplanted into spinal cord. Neuroreport. 2004;15(7):1117–1120
  40. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863–868
  41. Chin BB, Nakamoto Y, Bulte JW, Pittenger MF, Wahl R, Kraitchman DL. 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl Med Commun. 2003;24(11):1149–1154
  42. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169(1):12–20
  43. Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004;19(2):155–163

PII: S0969-8051(08)00066-8

doi: 10.1016/j.nucmedbio.2008.02.006

Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 579-588 , July 2008

Article Tools

* Image Usage & Resolution